← back to search

Jan Budczies

Incyte (United States) · DE
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Metabolomics and Mass Spectrometry Studies, and Cancer, Lipids, and Metabolism.
h-index
61
citations
23,834
works
429
NIH funding
primary concept
Medicine
email

Recent publications

Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samples
British Journal of Cancer 2026cited by 1position: middledoi
Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing
British Journal of Cancer 2026cited by 0position: middledoi
EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
Molecular Cancer 2025cited by 16position: middledoi
Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma
npj Precision Oncology 2025cited by 6position: lastdoi
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial
Molecular Cancer 2025cited by 3position: middledoi
Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins
Journal of Thoracic Oncology 2025cited by 3position: middledoi
Contribution of genetics to hematopoietic stem cell mobilization: a genomewide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor
Haematologica 2025cited by 2position: lastdoi
Comprehensive genomic profiling requires a blended ecosystem of learning healthcare and clinical trials
British Journal of Cancer 2025cited by 2position: middledoi
1980P Tumor mutational burden (TMB) and proliferation as negative prognostic factors for ALK+ lung cancer: First results from the randomized ABP phase II trial
Annals of Oncology 2025cited by 0position: middledoi
Tumour mutational burden: clinical utility, challenges and emerging improvements
Nature Reviews Clinical Oncology 2024cited by 114position: firstdoi
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency–Associated Genomic Instability in Ovarian Cancer
JCO Precision Oncology 2024cited by 17position: middledoi
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study
European Journal of Cancer 2024cited by 11position: middledoi
An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Clinical Cancer Research 2024cited by 10position: middledoi
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test
Journal of Molecular Diagnostics 2024cited by 6position: middledoi
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor
Journal of Molecular Diagnostics 2024cited by 1position: middledoi
The German Network for Personalized Medicine to enhance patient care and translational research
Nature Medicine 2023cited by 58position: middledoi
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients
npj Precision Oncology 2023cited by 32position: middledoi
Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer
British Journal of Cancer 2023cited by 28position: lastdoi
Real‐world data for precision cancer medicine—A European perspective
Genes Chromosomes and Cancer 2023cited by 20position: middledoi
Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
Translational Oncology 2023cited by 15position: lastdoi
Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
Cell Death Discovery 2023cited by 7position: lastdoi
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas
Lung Cancer 2023cited by 7position: middledoi
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
2023cited by 1position: middledoi
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
npj Precision Oncology 2022cited by 98position: lastdoi
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
British Journal of Cancer 2022cited by 69position: middledoi
<scp>Homologous recombination deficiency</scp> is inversely correlated with <scp>microsatellite instability</scp> and identifies immunologically cold tumors in most cancer types
The Journal of Pathology Clinical Research 2022cited by 32position: firstdoi
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions
European Journal of Cancer 2022cited by 25position: middledoi
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
Annals of Oncology 2021cited by 269position: middledoi
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
Annals of Oncology 2021cited by 179position: middledoi
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling
Seminars in Cancer Biology 2021cited by 88position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Albrecht Stenzinger · Chirurgische Universitätsklinik Heidelberg47 papers (2012–2025)Peter Schirmacher · Kliniken Essen-Mitte38 papers (2012–2025)Carsten Denkert · Frankfurt Cancer Institute26 papers (2013–2024)Volker Endris · Deutschen Konsortium für Translationale Krebsforschung25 papers (2014–2023)Martina Kirchner · Heidelberg University24 papers (2016–2026)Daniel Kazdal · Heidelberg University24 papers (2019–2025)Michael Allgäuer · Heidelberg University23 papers (2018–2024)Wilko Weichert · German Cancer Research Center19 papers (2012–2025)Olaf Neumann · Heidelberg University18 papers (2018–2024)Stefan Fröhling · German Cancer Research Center17 papers (2016–2024)Anna‐Lena Volckmar · Heidelberg University17 papers (2016–2025)Frederick Klauschen · Institute of Clinical Cancer Research16 papers (2014–2026)Klaus Kluck · Heidelberg University16 papers (2019–2025)Petros Christopoulos · Torbay Hospital14 papers (2018–2024)Michael Thomas · Barwon Health11 papers (2012–2023)Susanne Beck · University Hospital Heidelberg11 papers (2022–2026)Roland Penzel · Incyte (United States)11 papers (2015–2021)Eugen Rempel · University Hospital Heidelberg10 papers (2018–2022)Manfred Dietel · Charité - Universitätsmedizin Berlin10 papers (2013–2017)Michael Bockmayr · Universität Hamburg10 papers (2014–2021)